Richard Noppeney

Krankenhaus der Barmherzigen Brüder Trier — Germany

Medicine · Health Sciences

28h-index5.5kcitations99works4.12yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Acute Myeloid Leukemia Research(52), Multiple Myeloma Research and Treatments(24), Histone Deacetylase Inhibitors Research(16), Myeloproliferative Neoplasms: Diagnosis and Treatment(15), Acute Lymphoblastic Leukemia research(14)

Publications99 total

Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial
Blood·2025
Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group
Blood·2025Open Access
Crenolanib plus salvage chemotherapy improves outcomes in FLT3-mutant and NPM1 co-mutated relapsed/ refractory (R/R) Acute Myeloid Leukemia (AML): Results from a randomized, placebo-controlled, double-blind trial
Blood·2025Open Access
10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Blood·2025
Hypomethylating Therapy With or Without Eltrombopag in Elderly Patients With Acute Myeloid Leukemia: Results From the Randomized, Placebo‐Controlled Phase 2 <scp>DELTA</scp> Trial
American Journal of Hematology·2025Open Access
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Blood·2025· 12 citedOpen Access
Analysis of Early Apheresis Immunophenotype, Batch Data Variables and Clinical Outcomes for Optimization of CAR-T-Cell Therapy in Aggressive B-Cell Lymphomas
Blood·2024Open Access
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML: The Randomized DaunoDouble Trial by the Study Alliance Leukemia
Journal of Clinical Oncology·2024· 14 cited
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial
Blood·2024· 12 citedOpen Access
Die Erdheim-Chester-Erkrankung mit einer seltnenen Manifestation in der Orbita
Laryngo-Rhino-Otologie·2024
Erdheim-Chester disease, a rare manifestation in the orbit
Laryngo-Rhino-Otologie·2024
Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed <scp>AML</scp>: Results from the <scp>SAL‐MODULE phase I</scp> study
British Journal of Haematology·2024· 11 citedOpen Access
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapy
European Journal of Nuclear Medicine and Molecular Imaging·2023· 11 citedOpen Access
Salvage Autologous Transplant and Lenalidomide Maintenance Versus Continuous Lenalidomide/Dexamethasone for Relapsed Multiple Myeloma: Long Term Follow up Results of the Randomized GMMG Phase III Multicenter Trial Relapse
Blood·2023· 3 cited
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial
The Lancet Haematology·2023· 32 citedOpen Access
P554: RESULTS OF A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY OF HYPOMETHYLATING AGENTS WITH OR WITHOUT ELTROMBOPAG IN ELDERLY AML PATIENTS (DELTA)
HemaSphere·2023Open Access
UBTF tandem duplications are rare but recurrent alterations in adult AML and associated with younger age, myelodysplasia, and inferior outcome
Blood Cancer Journal·2023· 18 citedOpen Access
Outcome Prediction in Patients With Large B-cell Lymphoma Undergoing Chimeric Antigen Receptor T-cell Therapy
HemaSphere·2023· 15 citedOpen Access
Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups
Blood·2022· 4 cited
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML: Results from the Randomized Controlled SAL Dauno-Double Trial
Blood·2022· 17 cited
page 1 of 5Next →

Frequent Co-authors

Carsten Müller‐Tidow(25), Hubert Serve(22), Christoph Röllig(19), Christian Thiede(19), Andreas Neubauer(18), Gerhard Ehninger(18), Claudia D. Baldus(17), Wolfgang E. Berdel(17), Stefan W. Krause(16), Martin Bornhäuser(16), Markus Schaich(15), Hermann Einsele(14), Kerstin Schäfer‐Eckart(14), Mathias Hänel(14), Johannes Schetelig(14), Uwe Platzbecker(14), Alwin Krämer(13), Michael Krämer(13), Björn Steffen(13), Volker Kunzmann(12)